Evidence map›Paper›PMID 34721713›Full record

ReviewNuclear medicine and molecular imaging2021

KSNM60 in Non-thyroidal Radionuclide Therapy: Leaping into the Future.

Byung Hyun Byun, Myoung Hyoun Kim, Yeon-Hee Han, Hwan-Jeong Jeong

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Byung Hyun Byun *Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, South Korea.
Myoung Hyoun Kim *Department of Nuclear Medicine, Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Jeollabuk-do South Korea.
Yeon-Hee HanDepartment of Nuclear Medicine, Research Institute of Clinical Medicine of Jeonbuk National University and Biomedical Research Institute of Jeonbuk National University Hospital, 20, Geonji-ro, Duckjin-gu, Jeonju-si, Jeollabuk-do 561-803 South Korea.
Hwan-Jeong JeongDepartment of Nuclear Medicine, Research Institute of Clinical Medicine of Jeonbuk National University and Biomedical Research Institute of Jeonbuk National University Hospital, 20, Geonji-ro, Duckjin-gu, Jeonju-si, Jeollabuk-do 561-803 South Korea.
Jeonbuk National University · KRKorea Institute of Radiological and Medical Sciences · KRWonkwang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very important role in the development of nuclear medicine. Since I-131 was used for thyroid therapy in 1959, other radionuclide therapy is still being used, and attempts to use new radionuclide are increasing. In this review, we briefly summarize and introduce the therapies such as radioimmunotherapy, transarterial radioembolization, radionuclide therapy for neuroendocrine tumors, peptide receptor radionuclide therapy, control of metastatic bone pain, radiation synovectomy, radionuclide brachytherapy, alpha particle therapy, and boron neutron capture therapy, which has been being attempted so far in the field of nuclear medicine.

Indexed as

Alpha particleBoron neutron captureKoreaNuclear medicinePeptide receptorRadioimmuno therapyRadionuclide therapyTransarterial radioembolization

Identifiers

PMID34721713
PMCPMC8517045
OpenAlexW3195103336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.